China-Exclusive Cancer Therapies in 2026: Savolitinib, CAR-NKT & Beyond — A Patient Guide

Introduction

China's oncology landscape has undergone a remarkable transformation over the past decade. The National Medical Products Administration (NMPA) has accelerated approval pathways for innovative therapies, and Chinese research institutions are now conducting some of the world's most significant clinical trials in cancer treatment. The result is that a growing number of therapies are available to patients in China — approved and in clinical use — that have not yet received regulatory approval in the United States, Europe, or other markets.

For international patients, this creates a genuine opportunity: access to treatments that may not be available at home, delivered by experienced specialists at Shanghai's leading cancer centers.

This guide explains the most significant China-exclusive or China-leading cancer therapies in 2026, who they may be suitable for, and how China Medical Concierge Shanghai (CMCS) helps international patients evaluate and access them safely and legally.

Important note: All treatment decisions must be made by qualified oncologists based on individual patient assessment. CMCS provides coordination services, not medical advice. The information in this guide is for educational purposes only.

Section 1 — Savolitinib (Savolitinib / 沃利替尼)

What Is Savolitinib?

Savolitinib is a highly selective MET tyrosine kinase inhibitor, developed jointly by AstraZeneca and HUTCHMED (formerly Hutchison MediPharma). It targets the MET/HGF signaling pathway, which plays a key role in tumor growth and metastasis in certain cancers.

In 2021, the NMPA approved Savolitinib for the treatment of adults with MET exon 14 skipping mutation-positive (METex14) non-small cell lung cancer (NSCLC) who have progressed following prior systemic therapy. This made China one of the first countries in the world to approve a dedicated MET inhibitor for this indication.

Who May Be Suitable?

Savolitinib may be relevant for patients with:

• Non-small cell lung cancer (NSCLC) with a confirmed MET exon 14 skipping mutation
• Disease progression following prior platinum-based chemotherapy or immunotherapy
• Adequate organ function and performance status as assessed by an oncologist

The METex14 mutation occurs in approximately 3–4% of NSCLC patients. It is identified through next-generation sequencing (NGS) of tumor tissue or liquid biopsy. If you have not yet had NGS testing, this is the essential first step.

How Does It Compare to Other MET Inhibitors?

Other MET inhibitors — including Tepotinib (approved in Japan, USA, EU) and Capmatinib (approved in USA, EU) — target the same mutation. Savolitinib has been studied extensively in Chinese patient populations and has a well-characterized safety and efficacy profile in this context. Your Shanghai oncologist can review your specific case and discuss which option is most appropriate.

Current Availability Outside China

As of 2026, Savolitinib is approved in China and has received approval in certain other markets for specific indications. Regulatory review is ongoing in additional regions. Patients outside China who carry the METex14 mutation and have not responded to available therapies may find that Shanghai offers access to Savolitinib within a fully regulated clinical environment.

How CMCS Can Help

• Review your existing NGS results to confirm METex14 mutation status
• Arrange a remote pre-consultation with a Shanghai lung cancer specialist to assess suitability
• Coordinate hospital admission, treatment initiation, and monitoring
• Facilitate communication between your Shanghai oncologist and your home-country medical team

Section 2 — CAR-NKT Cell Therapy

What Is CAR-NKT?

CAR-NKT therapy combines two powerful concepts in cancer immunotherapy: Chimeric Antigen Receptor (CAR) technology — the same principle behind approved CAR-T therapies — and Natural Killer T (NKT) cells, a specialized immune cell population with distinct anti-tumor properties.

Compared to conventional CAR-T therapy, CAR-NKT cells offer several theoretical advantages that are currently being investigated in clinical trials:

• Allogeneic (off-the-shelf) potential — NKT cells may be derived from healthy donors rather than the patient's own cells, potentially reducing manufacturing time and cost
• Reduced graft-versus-host disease (GvHD) risk — NKT cells have a lower propensity to attack host tissue compared to conventional T cells
• Activity against both hematological and solid tumors — an area where conventional CAR-T has shown more limited results

China is among the global leaders in CAR-NKT research, with multiple clinical trials underway at institutions in Shanghai and Beijing.

Current Clinical Stage

As of 2026, CAR-NKT therapy remains primarily in the clinical trial phase. Trials in China are investigating its use in:

• Relapsed or refractory hematological malignancies (lymphoma, leukemia)
• Selected solid tumors including hepatocellular carcinoma and lung cancer (early-phase trials)
• Patients who have relapsed following prior CAR-T therapy

This is an area of active and rapidly evolving research. Patients considering CAR-NKT should understand that it is not yet a standard-of-care treatment, and eligibility is determined by strict clinical trial inclusion criteria.

Who May Be Eligible?

Eligibility for CAR-NKT clinical trials is determined on a case-by-case basis and typically requires:

• Confirmed diagnosis of a relevant hematological malignancy or solid tumor
• Relapsed or refractory disease after standard therapies
• Adequate organ function and performance status
• Absence of certain comorbidities as specified by the trial protocol

How CMCS Can Help

• Conduct a preliminary eligibility assessment based on your diagnosis and treatment history
• Connect you with the relevant Shanghai research center conducting the trial
• Support the full enrollment process: document preparation, translation, informed consent, and logistics
• Provide on-site coordination and interpretation throughout the trial period

Section 3 — Other China-Leading Therapies: An Overview

Beyond Savolitinib and CAR-NKT, several other therapies are either approved in China ahead of other markets or are in advanced clinical development at Chinese institutions.

This table reflects the landscape as of 2026 and is subject to change as regulatory approvals evolve globally. CMCS can provide an up-to-date assessment relevant to your specific diagnosis.

Section 4 — How to Access These Therapies: A Step-by-Step Process

Step 1 — Confirm Molecular Eligibility

Most targeted therapies require specific biomarker confirmation. If you have not yet had comprehensive molecular testing (NGS panel, IHC, FISH as appropriate), this is the essential starting point. If you have existing test results, CMCS will arrange for a Shanghai specialist to review them and advise on their relevance to available therapies.

Step 2 — Remote Specialist Pre-Consultation

Before any travel is considered, CMCS arranges a remote consultation — written or video — with the relevant Shanghai specialist. You receive a written assessment in English outlining whether a specific therapy is appropriate for your case, and what the proposed treatment pathway would involve.

Step 3 — Decide: Clinical Trial vs. Approved Therapy

Depending on your situation, there may be two pathways:

• Approved therapy (e.g., Savolitinib, Apatinib): available as standard clinical care at Shanghai hospitals, with transparent cost structures
• Clinical trial enrollment (e.g., CAR-NKT): subject to eligibility criteria; CMCS supports the full enrollment process

Your CMCS case manager will explain the practical and financial implications of each pathway clearly.

Step 4 — Travel and Treatment Coordination

Once you decide to proceed, CMCS coordinates every aspect of your Shanghai visit: visa guidance, hospital admission, treatment scheduling, accommodation near the hospital, and professional medical interpretation throughout.

Step 5 — Ongoing Monitoring and Follow-Up

After treatment begins or is completed, CMCS facilitates remote follow-up with your Shanghai specialist. We prepare structured treatment summaries for your home-country oncology team, ensuring continuity of care and informed monitoring of your response to therapy.

Section 5 — Important Considerations for Patients

• All treatment decisions must be made by qualified oncologists based on your individual clinical situation. CMCS provides coordination and access — not medical advice.
• Discuss with your home-country oncologist before pursuing any therapy abroad. Continuity of care and informed communication between your medical teams is essential.
• Clinical trials have strict eligibility criteria. Not every patient will qualify, and CMCS will provide an honest preliminary assessment before any commitments are made.
• Regulatory status evolves. Some therapies described here may receive approval in additional markets during 2026 and beyond. CMCS can advise on the current status at the time of your inquiry.
• Costs vary depending on the therapy, duration of treatment, and hospital. CMCS provides transparent cost information as part of the pre-consultation process.

Begin Your Assessment

If you or a family member has been diagnosed with cancer and you are exploring whether China's innovative therapies may offer additional options, CMCS is here to help you find out — remotely, without obligation, and with full transparency.

Send us your diagnosis summary and any existing molecular test results to begin.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com

CMCS — China Medical Concierge Shanghai. Helping international patients access China's most advanced cancer therapies, with full remote coordination from day one.